Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Niki BioSolutions's Enterprise Value is $-1.61 Mil.
Niki BioSolutions's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil. Therefore, Niki BioSolutions's EV-to-FCF for today is .
The historical rank and industry rank for Niki BioSolutions's EV-to-FCF or its related term are showing as below:
NIKI'
s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.88
Current: 0.88
During the past 9 years, the highest EV-to-FCF of Niki BioSolutions was 0.88. The lowest was 0.00. And the median was 0.00.
NIKI's EV-to-FCF is ranked better than 78.04% of 337
companies
in the Biotechnology industry
Industry Median: 15.15
vs NIKI: 0.88
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Niki BioSolutions's PE Ratio (TTM) for today is calculated as:
Niki BioSolutions's share price for today is $9.54.
Niki BioSolutions's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.300.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Niki BioSolutions EV-to-FCF Related Terms
Niki BioSolutions EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Niki BioSolutions's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Niki BioSolutions's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Niki BioSolutions EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Niki BioSolutions's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Niki BioSolutions's EV-to-FCF falls into.
Niki BioSolutions's current Enterprise Value is $-1.61 Mil.
Niki BioSolutions's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is Niki BioSolutions (NIKI) Overvalued in 2026?
Based on GuruFocus' analysis, Niki BioSolutions stock appears to be undervalued.
The current stock price of $9.54 is trading 18.4% below its estimated GF Value™ of $11.69.
GuruFocus considers Niki BioSolutions to be Modestly Undervalued.
Key valuation signals for NIKI:
EV-to-FCF:
GF Value™: $11.69 vs. price of $9.54 (18.4% below fair value)
No single metric tells the full story. See the NIKI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.
56GF Score
Get the complete analysis for NIKI
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NIKI has been successfully added to your 
